$8.39▴ 1.94%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
+88.0%year over year
Strong
Revenue is growing strongly year over year.
Leverage
Highdebt to assets
Weak
High leverage relative to its assets.
More coming: dilution / share-count creep.
✦ The read
Phathom Pharmaceuticals, Inc.'s earnings-quality signal is not available yet. Revenue is growing strongly year over year. High leverage relative to its assets.
Key numbers
Valuation
EPS (TTM)$-1.26
TTM (trailing 12 months, through fiscal Q2 FY2026)
Profitability
Net margin-41.3%
TTM (trailing 12 months, through fiscal Q2 FY2026)
Size
Revenue (TTM)$239.66M
TTM (trailing 12 months, through fiscal Q2 FY2026)
Signals and key numbers are from the fiscal Q2 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.